stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) EPS (diluted)
ADMA Biologics Inc's EPS (diluted) for fiscal 2025 was $0.60, down 25.9% from $0.81 in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.77. Over the past ten years it has ranged from −$1.91 (fiscal 2017) to $0.81 (fiscal 2024); the current reading is higher than 91% of that period. ADMA Biologics Inc ranks 40th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.60 | (25.93%) |
| FY2024 | $0.81 | — |
| FY2023 | −$0.13 | — |
| FY2022 | −$0.33 | — |
| FY2021 | −$0.51 | — |
| FY2020 | −$0.88 | — |
| FY2019 | −$0.89 | — |
| FY2018 | −$1.45 | — |
| FY2017 | −$1.91 | — |
| FY2016 | −$1.61 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.22 | 37.50% |
| Jun 2026 | $0.16 | (15.79%) |
| Mar 2026 | $0.19 | (5.00%) |
| Dec 2025 | $0.20 | 33.33% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $2.29 |
| ADMA ADMA Biologics Inc | $0.77 |
| VCEL Vericel Corporation compare | $0.65 |
| IMNM Immunome, Inc. compare | −$2.53 |
| PHVS Pharvaris N.V. compare | −$3.05 |
| BHVN Biohaven Ltd. compare | −$3.86 |
| CLDX Celldex Therapeutics, Inc. compare | −$4.35 |
| PVLA Palvella Therapeutics, Inc. compare | −$4.83 |
| VERA Vera Therapeutics, Inc. compare | −$5.86 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ADMA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement